Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Mehr anzeigen
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present...
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.28 | -3.00469483568 | 42.6 | 43.52 | 41.32 | 452631 | 42.57764946 | CS |
| 4 | -1 | -2.3629489603 | 42.32 | 43.52 | 40.03 | 386429 | 41.88759883 | CS |
| 12 | 1.84 | 4.66058763931 | 39.48 | 48.89 | 38.15 | 374900 | 42.44416924 | CS |
| 26 | 4.62 | 12.5885558583 | 36.7 | 48.89 | 35.63 | 439113 | 41.16796626 | CS |
| 52 | 13.79 | 50.0908100254 | 27.53 | 48.89 | 23.14 | 527312 | 33.56248054 | CS |
| 156 | 25.97 | 169.185667752 | 15.35 | 48.89 | 14.63 | 447557 | 28.68880456 | CS |
| 260 | 21.37 | 107.117794486 | 19.95 | 48.89 | 9.14 | 314962 | 27.03259546 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
